Prosecution Insights
Prosecution Insights
Technology area: Chemistry & Materials
4 pending office actions • 1 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Genequantum Healthcare (Suzhou) Co. Ltd. is managing 4 pending office actions in the Chemistry & Materials technology area. These actions are distributed among 3 distinct examiners, meaning at least 1 examiner is handling more than 1 case. All 4 pending office actions are being prosecuted within a single 1 distinct art unit, indicating a very narrow technical focus for the company's current filings.
PUTTLITZ, KARL J is the busiest examiner, responsible for 2 busiest examiner pending office actions. This accounts for 2 of the 4 total pending office actions for the company. The remaining actions are split between the other distinct examiners, all within the same 1 distinct art unit. This structure suggests a highly concentrated review process, where the outcome of the 4 pending office actions is determined by a small group of 3 distinct examiners working in the same technical unit. This concentration may lead to a more uniform examination experience across the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 2 | 69.1% | +18.6% |
| EVANS, JASMINE AFIYA | 1 | — | — |
| NGUYEN, TAM M | 1 | 77.1% | +11.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | EVANS, JASMINE AFIYA | — |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001764 | NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY | NGUYEN, TAM M | 25d overdue |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — |
| 18408826 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1771 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | EVANS, JASMINE AFIYA | — | §103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18408826 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — | §103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18001764 | NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY | NGUYEN, TAM M | 1771 | §103 | Final Rejection | 25d overdue | Pending | Dec 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial